Inclusion Criteria:

- Participants who are aged >=12 years at the time of signing Informed Consent Form

- Confirmed diagnosis of MOGAD with a history of >=1 MOGAD relapse in the 12 months prior to screening or >=2 attacks in the 24 months prior to screening

- Expanded Disability Status Scale (EDSS) score of 0-6.5 at screening

- Best corrected visual acuity (BCVA) better than 20/800 in each eye at screening

- Participants receiving either no or ongoing chronic immunosuppressant treatment (IST) for MOGAD at the time of screening

- For women of childbearing potential: participants who agree to remain abstinent or use adequate contraception during the treatment period and for at least 3 months after the final dose of satralizumab

Exclusion Criteria:

- Presence of aquaporin-4-antibodies (AQP4-IgG) in the serum

- History of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis

- Any concomitant disease other than MOGAD that may require treatment with ISTs or OCS or intravenous (IV) corticosteroids at doses  > 20 mg prednisone equivalent per day for >21 days during the study

- Participants who are pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of satralizumab

- Participants with active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline

- Participants with evidence of latent or active tuberculosis (excluding patients receiving chemoprophylaxis for latent tuberculosis infection)

- Participants with positive screening tests for hepatitis B and C

- Receipt of live or live attenuated vaccine within 6 weeks prior to baseline

- History of severe allergic reaction to a biologic agent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/2/23. Questions regarding updates should be directed to the study team contact.